NCT04434248 - An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19 | Biotech Hunter

Enrollment

330

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions

COVID-19

Interventions

DRUG

Favipiravir

200 mg coated tablets

DRUG

Standard of Care

Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.

Trial Locations (22)

Unknown

Republican Clinical Hospital, Makhachkala

"K+31 Clinic", Moscow

"Khaven Llc", Moscow

Central Clinical Hospital with Polyclinic, Moscow

Central Research Institute of Epidemiology, Moscow

City Clinical Hospital n.a. O.M. Filatov, Moscow

City Clinical Hospital named after S.S. Yudin, Moscow

City Clinical Hospital No. 24, Moscow

City Clinical Hospital No. 51, Moscow

First Moscow State Medical University n.a. I.M. Sechenov, Moscow

Moscow State University n.a. M. V. Lomonosov, Moscow

National Medical and Surgical Center named after N.I. Pirogov, Moscow

City Hospital № 33 of the Leninsky region of Nizhny Novgorod, Nizhny Novgorod

Infectious clinical hospital No.2 of Nizhny Novgorod, Nizhny Novgorod

Ryazan State Medical University named after I.P. Pavlov, Ryazan

Military Medical Academy named after S.M. Kirova, Saint Petersburg

Saratov State Medical University named after V.I. Razumovsky, Saratov

Clinical hospital No.1, Smolensk

Regional Clinic Hospital, Tver'

Bashkir State Medical University, Ufa

Yakutsk City Clinical Hospital, Yakutsk

Yaroslavl Regional Clinical Hospital for War Veterans, Yaroslavl